Auauniversity

AUA2023 Journal of Urology Lecture: Surgery Harms Surgeons. What can we do? Speaker: Dr. Kevin Turner

AUA2023 Ramon Guiteras Lecture: The Complicated Decisions Required to Eliminate Never Events Speaker: Dr Louis Kavoussi, Smith Institute For Urology.

AUA2023 John Duckett Memorial Lecture: Innovation by Necessity: Improving Urodynamics for Children with Spina Bifida Speaker: Dr. Johnathan Routh, Chief of Children's Surgery, Duke University School of Medicine.

AUA2023 John K. Lattimer Lecture: Innovation in Urology: From a Seminal “Why” to a Functional “How” Speaker: Dr. Ralph Clayman, Distinguished Professor / Endowed Chair in Endourology, University of California, Irvine.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer CME Available: https://auau.auanet.org/node/39542 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the rationale behind using adjuvant therapies in high-risk non-metastatic kidney cancer and the goals of adjuvant treatment. 2. Describe the adjuvant therapies that have been investigated to date for high-risk non-metastatic kidney cancer, including targeted therapies, immunotherapies, and combination approaches. 3. Discuss the challenges and limitations associated with adjuvant therapy trials in high-risk non-metastatic kidney cancer, such as patient selection, trial design, and long-term follow-up. ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC  Lantheus Medic

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: The Latest Breakthroughs in Immunotherapy for GU Cancers CME Available: https://auau.auanet.org/node/39543 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the newest immunotherapy drugs approved for prostate, bladder, and kidney cancer, including immune checkpoint inhibitors and other novel immunotherapies. 2. Discuss the clinical evidence supporting the use of these immunotherapy drugs in prostate, bladder, and kidney cancer, including data from pivotal clinical trials, response rates, and survival outcomes. 3. Evaluate the safety profile and potential immune-related adverse events associated with the newest immunotherapy drugs in GU cancers. ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC  Lantheus Medical Imaging Merc

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Germline Testing and Novel Approaches to Targeting Genetic Mutations in Prostate Cancer CME Available: auau.auanet.org/node/39487 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Identify the indications for germline testing in prostate cancer patients. 2. Explain how germline testing is used to identify genetic mutations in genitourinary (GU) cancers, specifically focusing on prostate cancer. 3. Analyze the potential advantages and challenges associated with using germline testing and targeted therapies in the management of prostate cancer. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astellas and Pfizer, Inc AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Novel Imaging for Genitourinary Cancers - Diagnostics and Theranostics CME Available: https://auau.auanet.org/node/39411 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Review the latest clinical trials investigating the use of PET imaging agents in prostate, kidney, and urothelial cancer, including their diagnostic accuracy and impact on patient management. 2. Discuss the available PET imaging agents for prostate cancer, with a specific focus on PSMA (Prostate-Specific Membrane Antigen) PET imaging, including its mechanism of action and its potential for detection of primary tumors, lymph node metastases, and distant metastases. 3. Discuss the benefits of incorporating PET imaging, including PSMA PET, in guiding treatment decisions for GU cancers, such as its impact on treatment selection, treatment response assessment, and the potential

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Early Detection of Prostate Cancer: AUA/SUO Guideline (2023) CME Available: https://auau.auanet.org/node/39410 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Discuss the potential benefits, limitations, and controversies associated with prostate cancer screening. 2. Summarize the key recommendations provided in the AUA/SUO Guideline regarding early detection strategies for prostate cancer. 3. Analyze the implications of the AUA/SUO Guideline on clinical practice, shared decision-making, and patient counseling regarding early detection of prostate cancer. ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  Astellas and Pfizer AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC  Lantheus Medical Imaging Merck & Co., Inc.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Treatment Paradigms for Intermediate and High-Risk Non-Muscle Invasive Bladder Cancer CME Available: https://auau.auanet.org/node/39374 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Describe the importance of individualized treatment decision-making and shared decision-making in the management of intermediate and high-risk NMIBC. 2. Discuss the challenges associated with BCG shortage and its impact on patient care and treatment decisions. 3. Evaluate alternative intravesical therapies for NMIBC, such as chemotherapeutic agents (e.g., mitomycin C, gemcitabine), novel immunotherapies (e.g., intravesical pembrolizumab), and clinical trials. ACKNOWLEDGEMENTS: Support provided by independent educational grants from:  AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC  Lantheus Medical Imaging Merck & Co., In

PARPi: Genetic Testing in Advanced Prostate Cancer - When and Who to Test (2023) CME Available: https://auau.auanet.org/node/39603 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, the learner will be able to: 1. Review recommended criteria for genetic testing of prostate cancer patients, currently available gene panels, and options for testing these men. 2. Explain the importance of testing for germline and somatic mutations and their implications for utilizing PARPi. 3. Describe work flows for genetic testing and utilization of genetic counselors. 4. Describe the genetic counseling process and the importance of pre-test counseling to discuss the benefits, limitations, and potential implications of germline testing for patients and their families. ACKNOWLEDGEMENT This educational activity is supported by an independent educational grant from Pfizer, Inc.

Infectious Complications Following Prostate Biopsy: Strategies for Reducing Infections and Reducing Health Care Costs CME Available: https://auau.auanet.org/node/39485 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to: 1. Describe health care costs associated with prostate biopsy infections. 2. Identify the steps where modifications in technique can reduce the risk of complications. 3. Apply modified technique at various steps of the procedures to mitigate the risk of complications. ACKNOWLEDGEMENT Project Firstline is a national collaborative led by the U.S. Centers for Disease Control and Prevention (CDC) to provide infection control training and education to frontline health care workers and public health personnel. AMA has partnered with Project Firstline, as supported through Cooperative Agreement CDC-RFA-CK20-2003.  The American Urological Association is proud to collaborate with AMA and Project Firstline

Germline Testing in GU Cancers – How I Do It CME Available: https://auau.auanet.org/node/39544 ACKNOWLEDGEMENTS: This series is supported by independent educational grants from:  AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC  Lantheus Medical Imaging Merck & Co., Inc. LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Differentiate between germline and somatic testing in the context of GU cancers, understanding the fundamental differences in the types of genetic alterations detected and their implications for patients and their families. 2. Describe the genetic counseling process and the importance of pre-test counseling to discuss the benefits, limitations, and potential implications of germline testing. 3. Evaluate the clinical significance and impact of germline testing results on treatment decisions, surveillance recommendations, and family management.

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Treatment Intensification for Advanced Prostate Cancer CME Available: https://auau.auanet.org/node/39486 At the conclusion of these activities, participants will be able to: 1. Identify the latest developments in hormone therapy for advanced prostate cancer, including the use of novel treatments and combinations. 2. Discuss the concept of doublet and triplet therapy in advanced prostate cancer and its rationale in enhancing treatment efficacy. 3. Consider the challenges and future directions in implementing doublet and triplet therapy in clinical practice, including cost, accessibility, and patient selection. This series is supported by independent educational grants from: Astellas and Pfizer, Inc. AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc. REFERENCES: Freedland SJ, et al. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. NEJ

PARPi: Precision Medicine in Advanced Prostate Cancer (2023) CME Available: https://auau.auanet.org/node/39597 At the conclusion of this activity, the learner will be able to: 1. Describe the mechanism of action of PARP inhibitors and the differences among drugs in this class. 2. Describe the role of PARPi treatment alone and in combination with other cancer based therapies. 3. Discuss existing clinical trial data assessing the efficacy of PARPi in advanced prostate cancer and ongoing late phase trials for PARP inhibitors. 4. Recognize the need for a multidisciplinary team to provide care for patients with advanced prostate cancer. ACKNOWLEDGEMENT This educational activity is supported by an independent educational grant from: Pfizer, Inc.

Prostate Cancer Treatment Intensification Moderator: Dr. Jay D. Raman Guest: Dr. Michael S. Cookson Acknowledgement: This podcast was funded by and in collaboration with AZ. All opinions are that of the faculty and do not necessarily reflect those of AstraZeneca. Release Date: 11/8/2023 Expiration Date: 11/8/2024

Update Series (2023) Lesson 33: A Critical Appraisal of the 2021 AUA/SUFU Guideline on Adult Neurogenic Lower Urinary Tract Dysfunction Now in its 42nd installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information, please visit the AUA Update Series on the AUAUniversity: auau.auanet.org/update23

Disparities in Care and Barriers to Access for Patients with Advanced Prostate Cancer At the conclusion of these activities, participants will be able to: 1. Recognize current patterns of use for systemic therapies in patients with advanced prostate cancer. 2. Identify disparities in access to care with respect to advanced prostate cancer treatment (ie. race, geography, socioeconomics). 3. Understand opportunities to improve quality and compliance with ADT treatment across different treatment populations. 4. Appreciate financial challenges that may be associated with current therapy options for advanced prostate cancer. 5. Apply treatment approaches that improve patient adherence to ADT including use of oral and parenteral therapies. ACKNOWLEDGEMENTS: This series is supported by independent educational grants from: Myovant Sciences LTD Pfizer, Inc. REFERENCES: Benjamin, D.J., Shrestha, A., Fellman, D. et al. Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from t

Systemic Therapies for Advanced Prostate Cancer – Short and Long-Term Side Effects CME Available: https://auau.auanet.org/node/39087 At the conclusion of these activities, participants will be able to: 1. Characterize current treatment paradigm for systemic therapies in managing advanced prostate cancer including doublet and triple therapy. 2. Identify short and long-term side effects of ADT and novel hormonal treatments for advanced prostate cancer including cardiovascular, bone health, and metabolic risk. 3. Recognize strategies to monitor and manage side effects of ADT and novel hormonal treatments. 4. Understand adverse effects of newer agents for advanced prostate cancer including PARP inhibitors, immunotherapy, and theranostics. 5. Review management options for adverse effects of newer agents for advanced prostate cancer. This series is supported by independent educational grants from:  Myovant Sciences LTD Pfizer, Inc. REFERENCES: 1. Association of androgen deprivation therapy with cardiovascular d

Genetic Testing and Stone Disease Co-host: Kyle Wood, MD Population analysis demonstrated that genetic conditions resulting in stone disease are magnitudes higher than those seen in clinical cohorts, suggesting underdiagnosis. Urologist play a unique role as we often times have many touch points with these patient given their presentation for stone disease. With the advancement of treatments, specifically in primary hyperoxaluria, it is essential that urologist play a more active role in the earlier diagnosis of patients. Genetic testing has become readily available at lower cost and much of the perceived barriers to genetic testing are addressed by current available programs. Outline: 1. The contribution of genetics to kidney stone disease 2. Specific studies using genetic testing 3. Primary Hyperoxaluria as an example 4. Current Genetic Testing and Ease 5. The role of the Urologist References: - Hill AJ, Basourakos SP, Lewicki P, et al. Incidence of kidney stones in the United States: The Continuous N